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Background: Mucosa-associated lymphoid tissue (MALT) lymphoma, a low-grade B-cell extrano-
dal lymphoma, is the most frequent subset of primary pulmonary lymphoma (PPL). It often
associates with connective tissue disease (CTD). We aimed to evaluate the impact of concom-
itant CTD on diagnostic value of flow cytometry and genetic clonality analyses for the diag-
nostic of MALT lymphoma.Pneumologie et Re´animation, Hoˆpital Tenon, 4 rue de la Chine 75970, Cedex 20, Paris, France.
56 01 69 91.
aphp.fr (M. Wislez).
1 Elsevier Ltd. All rights reserved.
1232 R. Borie et al.Sjogren’s syndrome;
Connective tissue
diseaseMethods: All chest disease and pathology departments of teaching hospitals in Paris were con-
tacted to identify patients with a histological diagnosis of PPL of the MALT subtype with or
without associated CTD. We identified 44 patients in the lymphoma group; 11 had a CTD and
were matched to 11 patients with CTD but without lymphoma.
Results: Results of BAL analyses of MALT-PPL showed normal cellularity (370 cells/mm3 [range
21e2300]) but increased proportion of lymphocytes (31.5% [80e2]) of the B-cell subtype (20%
[1e88]). A B-cell clone was detected in 82% of cases, and specificity of clonality was 90%. Inter-
estingly, BAL analysis results different by presence or not of a CTD. The frequency of B lympho-
cyte alveolitis was significantly greater in MALT patients without than with CTD (34% vs 6.5%,
pZ 0.007). However, BAL results for patients with CTD did not differ between those with and
without lymphoma.
Conclusion: BAL results may be highly suggestive of pulmonary MALT lymphoma. The propor-
tion of B-cells may vary depending on the presence of an associated CTD, but clonality analyses
remained informative for the diagnostic of MALT lymphoma.
ª 2011 Elsevier Ltd. All rights reserved.Introduction
Mucosa-associated lymphoid tissue-derived (MALT) lymphoma
is the most frequent subset of primary pulmonary lymphoma
(PPL), and lung location represents 15% of cases.1 Clinical
presentation is not specific, and 36% of the patients are
asymptomatic.2 Diagnosis should be suspected in patients
with chronic alveolar opacity, usuallywith anair bronchogram
and no pleural effusion ormediastinal adenopathy.3 Diagnosis
requires biopsies such as bronchial, transbronchial, percuta-
neous or even invasive methods such as surgical open lung
biopsies for histological analysis and immunohistological
staining. However, the detection of a strong B-cell clonal
population in bronchoalveolar lavage (BAL) fluid may be
strongly predictive of specific pulmonary infiltration, what-
ever the type of lymphoma, which contributes to the diag-
nosis.4e5 Up to 16% of the patient with pulmonary MALT
lymphoma have an associated connective tissue disease
(CTD),2 wich could interfere with the results of BAL.6
We therefore undertook this study to evaluate the influ-
ence of the presence of an associated CTD on BAL character-
istics in histologically confirmed pulmonary MALT lymphoma.
Patients and methods
Patients
All chest disease departments in adult teaching hospitals in
Paris (n Z 15) were contacted to identify patients with
a diagnosis of pulmonary MALT lymphoma between January
1, 1993 and February 1, 2008. Moreover, the pathology
departments attached to each hospital were asked to
report on cases diagnosed during the same time.
To be included in the study, patients had to have
- MALT lymphoma histologically proven according to the
World Health Association classification7;
- Initial pulmonary location of MALT lymphoma assessed
by CT scan;
- No extra-pulmonary node involvement nor chronic
lymphocytic leukemia; and
- Available BAL data.Patients with another histological subtype of lymphoma,
including diffuse large B-cell lymphoma, or with pulmonary
relapse of MALT lymphoma without evidence of an initial
pulmonary location were excluded.
Data and staging information were collected as previ-
ously reported2 by a standardized and anonymous collec-
tion form. Particular attention was paid to the presence
or not of a CTD categorized as follows: systemic lupus
erythematosus and rheumatoid arthritis according to the
American College of Rheumatology criteria, dermatomyo-
sitis and/or polymyositis according to Troyanov criteria7
and Sjogren’s syndrome according to the revised Amer-
ican-European Consensus Group criteria.8 Patients were
classified as having undifferentiated connective tissue
disease close to Sjogren’s syndrome according to modified
Kinder criteria9: sicca symptoms or signs, anti-SSA anti-
bodies or lip biopsy focus score >1 without definite
criteria for Sjogren’s syndrome. Pathology reports were
centrally reviewed by a pathologist expert in oncology
(MA).
To understand the impact of an associated CTD on BAL
findings, patients with CTD-associated MALT lymphoma
were matched by gender, age and cigarette smoking to
a control group of patients with CTD but without lymphoma
who underwent BAL for interstitial lung disease.
This study was approved by the Institutional Review
Board of the French learned society for respiratory medi-
cine Socie´te´ de Pneumologie de Langue Franc¸aise
(2009e003). For this observational, non-interventional
analysis of medical records, French law does not require
the consent of patients.BAL, lymphocyte phenotyping, clonality analysis
The following BAL data were collected:
- BAL positioned in the abnormal territory,
- Specific staining and cultures for bacteria and
mycobacteria,
- Cytologic analysis with differential cell count,
- Lymphocyte phenotyping,
- B-cell clonality analysis results.
BAL in pulmonary MALT lymphoma 1233The lymphocytes subsets were determined by flow
cytometry with the routine procedures of each cytological
laboratory attached to each chest disease department. All
antibody panels included anti-CD3, -CD4 and -CD8, and
anti-CD19 or -CD20 monoclonal antibodies for T and B
lymphocyte count respectively.
Whatever the chest disease department, 10 ml of fresh
BAL was routinely referred to the Laboratoire d’immuno-
logie-Biologique, Centre Hospitalier Henri Mondor, Creteil.
Briefly, DNA was obtained by a standard proteinase K
digestion and a phenol/chloroform extraction of BAL cells.
Then, the complementarity determining region 3 (CDR3)
was amplified by two PCR. Before 2003, in one PCR, the 50
sense oligonucleotide matched homologous sequences
within the framework (FR) 2 region; in the second PCR, it
matched homologous sequences within FR3 region.4
After 2003, 50 sense oligonucleotide matched homologous
sequences within FR2 and FR1 region according to European
protocol.10 Clonality analysis interpreted as previously
reported.4 The amplified products were run on an ABI
genetic analyzer for length diversity analysis (Applied Bio-
systems, Courtaboeuf, France). Results were analyzed by
use of Genscan analysis software (Applied Biosystems).
Samples with a unique dominant peak within the polyclonal
background were considered clonal, and the clonal pop-
ulation was characterized by CDR3 size. A peak was
“strong” when it was associated with low or absent poly-
clonal background and considered clonal. Samples with
multiple dominant peaks (oligoclonal) or samples with
a polyclonal repertoire were considered nonclonal.
Statistical analysis
Data for continuous variables are expressed as median
(range) and were compared by the ManneWhitney U test.
Categorical variables are expressed as number and
percentage and were compared by Fisher’s exact test. All
tests were two-sided, with p < 0.05 indicating statistical
significance. All analyses involved use of the R software
(www.r-project.org, Bell Laboratories).Results
All 15 chest disease departments participated. Four of the 15
departments did not have any eligible cases.We identified 63
cases of pulmonary lymphoma diagnosed between January 1,
1993, and February 1, 2008; characteristics of these cases
were described previously.2 BAL data were available for 44
patients whowere included in the present study. Twenty-two
patients hadanextra-pulmonary locationof lymphomawhom
12 with a gastric location of the lymphoma (41 specifically
evaluated) and 6 with medullar location (42 evaluated). On
the thoracic CT scan, seven patients had mediastinal aden-
opathy less than 2 cm in diameter and 2 patients had a mild
pleural effusion not specifically evaluated.
Patients with MALT lymphoma
In total, 21 patients were women (47%). The median age
was 57.9 years [range 30e76 years] (Table 1). Five (11%)were active smokers, and 13 (29%) former smokers. None of
the evaluated patients had HIV infection (0/29 tested).
Eleven patients had CTD at diagnosis (25%), including
systemic lupus erythematosus (nZ 2), rheumatoid arthritis
and Sjogren’s syndrome (n Z 1), primary Sjogren’s
syndrome (n Z 4); 4 additional patients had undifferenti-
ated connective tissue disease close to Sjogren’s syndrome.
Patients with CTD were most frequently non-smoker
women (Table 1).Bronchoalveolar lavage
MALT lymphoma
Cell count
Total BAL cell count was normal (370 cells/mm3
[21e2300]), as was proportion of neutrophils and eosino-
phils (3.5% [0e66] and 0.5% [0e8]). The proportion of
lymphocytes was increased (31.5% [2e80]) and resulted in
a reduced proportion of macrophages (52.5% [16e97]).
Lymphocytes represented more than 15% of total BAL cells
in 37 out of 44 cases (84%) (Table 1, Fig. 1).
Lymphocyte phenotyping and clonality analysis
Results of BAL lymphocyte phenotyping available for 27 BAL
findings (61%) were as follows. The median T lymphocyte
proportion (CD3) of alveolar lymphocytes was 68% [7e92],
the median CD3þCD4þ proportion 27% [4e77] and the
median CD3þCD8þ proportion 25% [2e80]. The median B
lymphocyte proportion (CD19 or CD20) of total alveolar
lymphocytes was 20% [1e88], and B lymphocytes repre-
sented more than 15% of total alveolar lymphocytes in 18
out of 27 cases (66%) (Table 1).
Clonality analysis of alveolar B-cells was available for 23
cases (52%), among which 19 showed a strong B-cell clone
(82%) (Table 1). Finally, both B-cell phenotyping and clon-
ality analysis were available for 19 BAL (43%), among which
11 (57%) showed both high B lymphocyte count (>15% of
lymphocytes) and a strong B-cell clonal population.
MALT lymphoma associated or not with connective tissue
disease
Patients with lymphoma associated or not with CTD did not
differ in global cell counts (Fig. 2). However, as compared
with patients with CTD, those without CTD showed a higher
proportion of B lymphocytes (34% vs 6.5%, p Z 0.007) and
lower proportion of T lymphocytes on BAL (41% vs 89%,
p Z 0.003) (Fig. 3; Table 1). By contrast, T lymphocytes
were of the predominant CD3þCD8þ subtypes in patients
with CTD (38% vs 17%, p Z 0.006) (Fig. 3). Finally, patients
with CTD showed a less-frequent strong B-cell clonal pop-
ulation (66% vs 88%) (Table 1).
In addition there were no differences between the 2
groups regarding CT scan extension, extra-pulmonary
location or progression free survival.
Connective tissue disease without MALT lymphoma
Characteristics of patients with CTD but without pulmonary
lymphoma are in Table 2. The diseases were primary Sjog-
ren’s syndrome (n Z 7), rheumatoid arthritis and Sjogren’s
syndrome (n Z 1), and dermatomyositis (n Z 1); 2 addi-
tional patients showed undifferentiated connective tissue
Table 1 Main clinical and bronchoalveolar lavage (BAL) data for patients with mucosa-associated lymphoid tissue (MALT)
lymphoma in the global population and associated or not with a connective tissue disease. Data are number (percentage) for
categorical variables or median (range) for continuous variables. * is p test between with and without connective tissue disease.
Malt lymphoma
Global population
(n Z 44)
Without connective tissue disease
(n Z 33)
With connective tissue disease
(n Z 11)
p*
Age 57.9 (30e76) 56.8 (36e83) 60 (30e79)
Female 21 (46%) 12 (36%) 9 (81%) 0.02
Smoker 18 (40%) 17 (51%) 1 (9%) 0.03
Bronchoalveolar lavage
Cell (/mm3) 370 (21e2300) 300 (21e2300) 250 (80e390) NS
Macrophages % 52.5 (16e97) 48 (16e97) 70 (36e85) NS
Neutrophils % 3.5 (0e66) 3 (0e66) 3 (0e15) NS
Eosinophils % 0.5 (0e8) 0 (0e8) 0.5 (0e4) NS
Lymphocytes % 31.5 (2e80) 34 (2e80) 26 (4e61) NS
T cell (CD3) % 68 (7e92) 41 (18e80) 89 (63e93) 0.003
CD3þCD4þ 27 (4e77) 24 (4e77) 34 (23e70) NS
CD3þCD8þ 25 (2e80) 17 (2e63) 38 (18e80) 0.006
B-cell (CD19) % 20 (1e88) 34 (2e80) 6.5 (1e30) 0.007
Dominant B-cell clone 19 (82) 15 (88) 4 (66) NS
1234 R. Borie et al.disease close to Sjogren’s syndrome. Lung diseases were
lymphoid interstitial pneumonia (LIP, n Z 5), non-specific
interstitial pneumonia (NSIP, n Z 3), bronchiolitis (n Z 2),
organizing pneumonia (n Z 2), and subclinical lymphocyte
alveolitis (n Z 1). Patients could have more than one
definite lung disease.
Patients with CTDwith andwithout MALT lymphoma did not
differ in BALcell count or alveolar lymphocytephenotype (Figs.
2 and 3, Table 2). Positive clonality results weremore frequent
with MALT lymphoma (p Z 0.02) (Table 2). Indeed, clonality
results were negative for all patients but 1 without MALT
lymphoma. This patient had bronchiolitis, and pulmonary
lymphoma did not develop after a follow-up of 32 months.
Discussion
This study describes BAL findings for a large series of
patients with pulmonary MALT lymphoma. It confirms thatFigure 1 Differential bronchoalveolar lavage (BAL) cell
count in global population of 44 patients with pulmonary
mucosa-associated lymphoid tissue (MALT) lymphoma: BAL
analysis revealed normal cellularity with increased proportion
of lymphocytes.results of BAL analysis are predictive of MALT lymphoma of
such a diagnosis, showing lymphocyte alveolitis in 84% of
cases and an increased proportion of B lymphocytes (>15%
of total lymphocytes) in two-thirds of cases, and a B-cell
clonal population in 82% of cases. Altogether, sensitivity,
specificity of clonality analysis were 82%, 90% respectively.
When a CTD was associated with the lymphoma, sensitivity,
specificity, and positive and negative predictive values of
clonality analysis were reduced to 66%, 90%, respectively.
BAL results may be highly suggestive of pulmonary MALT
lymphoma. The proportion of B-cells may vary depending
on the presence of an associated CTD.
The high prevalence of CTD, essentially Sjogren’s
syndrome, in this series of MALT lymphoma is not fortu-
itous. Marginal-zone lymphoma is considered a model of
antigen-driven lymphoma, driven by autoantigens or mic-
robial pathogens.11 Indeed the risk of lymphoma isFigure 2 Percentage of alveolar lymphocytes. BAL analysis
revealed increased proportion of lymphocytes in the 4 groups
of patients: global population of MALT lymphoma, MALT
lymphoma associated or not with connective tissue disease
(CTD), and non-MALT lymphoma interstitial lung disease asso-
ciated with CTD.
Figure 3 Alveolar lymphocyte immunophenotyping: percentage of (A) CD4þ, (B) CD8þ, and (C) CD19þ lymphocytes. In the global
MALT population, BAL analysis revealed an increased proportion of B lymphocytes (CD19) and a decreased proportion of CD4þ and
CD8þ T lymphocytes. The proportion of T lymphocytes, particularly CD8þ lymphocytes, was reduced in the non-connective tissue
disease (CTD) subgroup (B), and that of B lymphocytes was increased in the non-CTD subgroup (C). )p < 0.05; nsZ non-significant.
BAL in pulmonary MALT lymphoma 1235estimated to be 6.6e44 times higher in Sjogren’s syndrome
than in the normal population,12e13 with marginal-zone
lymphoma the most frequent histological subtype of
lymphoma.12,14
BAL analysis reflects pulmonary cell infiltration.5,15 Indeed
it is widely used in interstitial pneumonia workup. In alveolar
proteinosis, or alveolar hemorrhage, BAL analysis may be
sufficient for the diagnosis of disease showing granular
material that stains with periodic acid-Schiff or haemorrhagic
and siderophagic alveolitis. In sarcoidosis or idiopathic
pulmonary fibrosis, BAL analysis may be helpful by showing
CD3þCD4þ lymphocyte alveolitis or elevated neutrophil andTable 2 Main clinical and BAL data for patients with connective
lung disease. Data are number (percentage) for categorical varia
Patients with connective tissue disease
MALT Lymphoma
(n Z 11)
N (%) 11
Age 60 (30e79)
Female 9 (81%)
Smoker 1 (9%)
Bronchoalveolar lavage
Cell (/mm3) 250 (80e390)
Lymphocyte % 25 (4e61)
T cell (CD3) % 89 (63e93)
CD3þCD4þ 34 (23e70)
CD3þCD8þ 38 (18e80)
B-cell (CD19) % 6.5 (1e30)
Positive B-cell clone 4 (66)eosinophil counts.16e17 In this series of MALT lymphoma, BAL
analysis revealed the proportion of alveolar B lymphocytosis
(>15%) increased in 66% of cases. For the one-third remaining
patients, BAL analysis revealed a median 27.5% of lympho-
cytes, 11% of which were B-cells. Some patients might have
not received BAL in the good territory. Moreover, BAL T cells
came from polyclonal reactive T lymphocytes surrounding
MALT lymphoma. These could mask the tumoral B-cell pop-
ulation and would impair the diagnosis.18
Comparison of BAL from lymphoma associated with CTD,
and CTD without lymphoma suggests that BAL fluid mostly
reflected underlying pulmonary involvement such as NSIP,tissue disease associated with MALT lymphoma or non-tumoral
bles or median (range) for continuous variables.
Non-MALT interstitial pneumonitis
(n Z 11)
p
11
61 (34e84) NS
10 (92%) NS
0 (0%) NS
290 (200e1000) NS
25 (3e80) NS
84 (71e96) NS
44 (28e59) NS
33 (27e52) NS
6.5 (0e25) NS
1 (9) 0.02
1236 R. Borie et al.LIP or organizing pneumonia. The results of BAL observed in
this group are in agreement with previously published
observations.6,19 In patients with CTD, with or without
lymphoma, BAL revealed lymphocyte alveolitis, represent-
ing 25% of total cell count, with the proportion of T
lymphocytes 84% and 89%, respectively. A subclinical
alveolitis of T lymphocytes is present in almost 50% of
patients with Sjogren’s syndrome.20 In LIP or NSIP,
lymphocyte alveolitis is variable, between 13% and 30%.6,19
Clonality analysis in routine practice is feasible. Case
reports suggested the usefulness of BAL clonality analysis
for diagnosis, and BAL fluid from 106 patients with sus-
pected pulmonary lymphoma had been prospectively
assessed by some of us4e5,15; in 22 patients, the pulmonary
location of lymphoma was confirmed, 10 of these showing
MALT lymphoma. Specificity and sensibility were in the
same range as reported here (i.e., 97% and 95%, respec-
tively). A positive test result should encourage investigation
leading to histological confirmation. In this series, one
patient with bronchiolitis without lymphoma had a positive
test result, which was considered false positive. This false-
positive result was confirmed on a second alveolar sample.
However, the patient did not show any pulmonary opacity
suggestive of lymphoma that would have justified open lung
biopsy. Development of lymphoma could be preceded by
monoclonal B-cells detected up to 36 months later.21 In our
case of bronchiolitis, no lymphoma occurred after 32
months of follow-up. However, numerous non-lymphoma-
tous situations may lead to the detection of positive B-cell
clonality. Indeed, current infection, polyclonal lymphoid
hyperplasia or solid neoplasm may lead to a B-cell clonal
population without lymphoma.22e23 Furthermore, clonality
was evaluated in lip histological samples from 14 patients
with Sjogren’s syndrome, and a clonal B-cell population was
present in 13 cases without further occurence of lymphoma
at a mean follow-up of 4.1 years.24 Those data highlight the
usefulness of clone intensity evaluation for positive pre-
dictive value of clonality analysis for the diagnosis of MALT
lymphoma as previously published.4 In any way, histological
diagnosis remained required and molecular clonality data
are only a tool toward the diagnosis.
This series confirms thatmonoclonal B alveolitis is frequent
in pulmonary MALT lymphoma. Our findings support the
routine assessment of lymphocyte phenotyping and clonality
with BAL in suspected diagnosis of MALT lymphoma. Lympho-
cytes are monotypic, typically CD19þ, CD20þ, CD22þ, CD5-,
CD10- and kappa or lambda.7,25 Indeed a prospective study
should evaluate the significance of more precise alveolar
lymphocyte phenotyping in non-Hodgkin pulmonary
lymphoma. We show here that association of a pulmonary
lymphoma with a CTD could impaired the detection of
a dominant B-cell clone either by flow cytometry and by
molecular biology, but positive predictive value remains
sufficient to still use BAL analyses in this clinical setting.Acknowledgments
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